OUR PRODUCTS

Our Pipeline

We challenge ourselves to rethink the way medicines are developed,
and are investing now to bring more value to patients in the future.

We strive for constant innovation and we are putting our passion and expertise to work in new areas including hematology, gastroenterology and endocrinology.

SB12

Biosimilar candidate

  • Molecule Eculizumab
  • Reference Biologic Soliris®ii
  • Therapeutic Area Hematology
SB15i

Biosimilar candidate

  • Molecule Aflibercept
  • Reference Biologic Eylea®iii
  • Therapeutic Area Ophthalmology
SB16

Biosimilar candidate

  • Molecule Denosumab
  • Reference Biologic Prolia®iv
  • Therapeutic Area Endocrinology
SB17

Biosimilar candidate

  • Molecule Ustekinumab
  • Reference Biologic Stelara®v
  • Therapeutic Area immunology
SB26

Novel biologic

  • Molecule Ulinastatin-Fc
    Fusion Protein
  • Therapeutic Area Gastroenterology

*Pipeline last updated Aug 2021

  • iPhase I clinical trial was waived for SB15
  • iiSoliris® is a registered trademark of Alexion
  • iiiEylea® is a registered trademark of Regeneron
  • ivProlia® is a registered trademark of Amgen
  • vStelara® is a registered trademark of Janssen
SAMSUNG BIOEPIS

확인 취소
레이어 팝업 닫기